EU/3/09/636: Orphan designation for the treatment of corneal graft rejection

Dexamethasone phosphate

Table of contents


Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.

On 15 April 2009, orphan designation (EU/3/09/636) was granted by the European Commission to Voisin Consulting S.A.R.L., France, for dexamethasone phosphate (iontophoretic solution, ocular use) for the treatment of corneal graft rejection.

The sponsorship was transferred to Eyegate Pharma SAS, France, in September 2010 and to Interface International Consultancy Ltd, United Kingdom, in May 2012.

The sponsorship was transferred to IDEA Innovative Drug European Associates Limited, United Kingdom, in May 2015.

Key facts

Active substance
Dexamethasone phosphate
Intended use
Treatment of corneal graft rejection
Orphan designation status
EU designation number
Date of designation
IDEA Innovative Drug European Associates Limited
19 Eastbourne Terrace
London W2 6LG
United Kingdom
Tel. +44 (0)20 3036 0764
Fax: + 44 (0)8723 310 455

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating